From: Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities
Cell type | Epigenetic modifier | Locus | Effects | References | |
---|---|---|---|---|---|
NK cells | DNMTs | DNA methyltransferase | DNA methylation | • Enhance IFN-γ expression • Regulate KIR expression | Chan et al. [63] Luetke-Eversloh et al [66] Sohlberg et al. [69] |
EZH2 | Histone methyltransferase | H3K27me3 | • Suppress IL-15R (CD122) and NKG2D expressions | Yin et al. [29] Bugide et al. [30] | |
ASH1L | Histone methyltransferase | H3K36me3 | • Positively regulate NK activation | Li et al. [62] | |
JARID2 | Histone methyltransferase | H3K27me3 | • Positively regulate NK activation | Li et al. [62] | |
KDM6B | Histone demethylase | H3K27me2/3 | • Positively regulate NK activation | Li et al. [62] | |
UTY | Histone demethylase | H3K27me | • Positively regulate NK activation | Li et al. [62] | |
Macrophages | DNMTs | DNA methyltransferase | DNA methylation at promoters of Klf4, Socs1, Pparg | • Promote M1 polarization | Cheng et al. [75] Yang et al. [76] Niu et al. [2] |
TET2 | Methylcytosine dioxygenases | DNA methylation at promoters of immunosuppressive genes | • Promote M2 polarization | Pan et al. [77] Lio et al. [23] | |
EHMT2 | Histone methyltransferase | H3K9me3 | • Suppress M1 polarization | Wang et al. [82] | |
ASH1L | Histone methyltransferase | H3K4me3 | • Suppress IL-6 and TNFα production | Xia et al. [197] | |
SETD4 | Histone methyltransferase | H3K4me1, H3K4me2 | • Induce macrophage activation • Increase IL-6 and TNFα expression | Zhong et al. [32] | |
SETD7 | Histone methyltransferase | H3K4me1 | • Promote M1 polarization, • Increased S100A9 and S100A12 expressions | Mossel et al. [83] | |
SMYD2 | Histone methyltransferase | H3K36me2 | • Negative regulation of macrophage activation | Xu et al. [78] | |
SMYD3 | Histone methyltransferase | H3K4me3 | • Promote M1 polarization, Increased S100A9 and S100A12 expressions | Mossel et al. [83] | |
SMYD5 | Histone methyltransferase | H4K20me3 | • Negative regulation of macrophage activation | Stender et al. [79] | |
KDM6B | Histone demethylase | H3K27me | • Promote M2 polarization | Ishii et al. [80] Satoh et al. [81] Yıldırım-Buharalıoğlu et al. [198] Xun et al. [34] Raines et al. [35] | |
HDAC11 | Histone deacetylase | AcH3 | • Inhibit M2 polarization and activation | Hu et al. [199] Shinohara et al. [38] | |
KAT2A/B | Histone acetyltransferase | H3K9ac | • Promote M2 activation • Increase IL-6 expression | Hu et al. [199] | |
EP300 | Histone acetyltransferase | Acetyl Histone H3 | • Promote M2 activation • Increase IL-6 expression | Wang et al. [84] | |
PRMT1 | Arginine methyltransferase | Arginine methylation of c-Myc | • Promote M2 activation | Tikhanovich et al. [85] | |
CD8 + T cells | DNMT3A | DNA methyltransferase | DNA methylation at promoters of Eomes, Tbx21 and Tcf7 and promoters of naive-associated genes | • Promote tumor-specific T cell dysfunction • Establish de novo DNA methylation program for T cell exhaustion • Repress naive-associated genes in effector CD8+ T cells | Schietinger et al [97] Ghoneim et al. [96] Youngblood et al [200] |
TET2 | Methylcytosine dioxygenases | DNA methylation | • Regulate CD8+ T cell memory differentiation • Promote terminal exhaustion of T cells | ||
EZH2 | Histone methyltransferase | H3K27me3 | • Promote SLEC and effector T cell differentiation • Anti-tumor immunity | Karantanos et al. [53] Schietinger et al. [97] Zhao et al. [202] Gray et al. [87] | |
EHMT2 | Histone methyltransferase | H3K9me3 | • Suppress the development of memory precursor CD8+ T cells • Repress Il2ra and Cd27 | Shin et al. [89] | |
BMI1 | Epigenetic repressor, Component of the polycomb group complex 1 (PRC1) | Targets of PRC1 complexes | • Promote T cell activation and expansion | ||
BRD4 | Bromodomain-containing protein | Acetylated lysines | • Promote T cell differentiation into an effector memory phenotype • Enhance T cell persistence and antitumor effects | Kagoya et al. [40] | |
HDAC2 | Histone deacetylase | Acetylated histones | • Suppress the development of memory precursor CD8+ T cells • Repress Il2ra and Cd27 | Shin et al. [89] | |
KDM1A (LSD1) | Histone demethylase | H3K4me, H3K9me | • Promote terminal differentiation in exhausted CD8 + T cells | Liu et al. [33] | |
SIRT1 | NAD+-dependent deacetylase | N/A | • Inhibit effector T cell differentiation | Kuroda et al. [204] | |
TOX | Transcription factor/Chromatin modifier | Binds DNA via the HMG-box motif | • Promote T cell persistence • Drive CD8+ T cell exhaustion | Khan et al. [101] Alfei et al. [103] Scott et al. [102] Yao et al. [205] Seo et al. [206] Wang et al. [207] | |
Treg | HDAC | Histone deacetylase | FOXP3 | • Decreased binding of FOXP3 to chromatin • Destabilize FOXP3+ Treg cells | Samanta et al. [39] |
EZH2 | Histone methyltransferase | H3K27me3 | • Mediate immunosuppressive functions in tumor-infiltrating Tregs | ||
Dendritic cells | TETs | Methylcytosine dioxygenases | DNA methylation | • Modulate dendritic cell activation | Li et al. [208] |
EZH2 | Histone methyltransferase | H3K27me | • Promote dendritic cell activation | Li et al. [124] | |
DOT1L | Histone methyltransferase | H3K79me2 | • Inhibit maturation of BMDCs in cancer | Zhou et al. [31] | |
HDAC | Histone deacetylase | Acetylated histones | • Promote maturation of DCs from monocyte | Nencioni et al. [122] | |
SIRT6 | NAD+-dependent deacetylase | H3K9ac | • Promote dendritic cell migration | Ferrara et al. [36] | |
MDSC | Class I HDACs | Class I histone deacetylases | Acetylated histones | • Promote immune suppressive activity of G-MDSC | Hashimoto et al. [36] |
HDAC2 | Class I histone deacetylase | Acetylated histones | • Promote phenotypic switch from M-MDSC to G-MDSC | Youn et al. [37] | |
HDAC6 | Class IIb histone deacetylase | Acetylated histones | • Promote immune suppressive activity of M-MDSC | Hashimoto et al. [36] | |
HDAC11 | Class VI histone deacetylase | Acetylated histones | • Negatively regulate MDSC expansion and function | Sahakian et al. [128] |